1

Medical data is for informational purposes only. You should always consult your family physician, or one of our referral physicians prior to treatment.

The Journal

Of The

Rheumatoid Disease

Medical Association

Volume 1, Number 1

Officers and Board Members:

President (Chairman): Gus J. Prosch, Jr., M.D.

Vice-Chairman: Sheldon Nelson, D.O.

Executive Director/Secretary: Wayne Martin, B.S.

Medical Journal Editor: Robert Bingham, M.D. (1986);

Stephan Cooter, Ph.D. (1994)

Chief Editor/Treasurer: Robert Bingham

Board Members:

Robert Bingham, M.D.; Warren M. Levin, M.D.; Orville Davis,

D.O., M.D.; W. W. Mittelstadt, D.O., M.D.; Archimedes A.

Concon, M.D.; Harley Robinson, D.O; Albert Jellen, M.D.

Research Advisory Board:

Harold Buttram, M.D.; Sheldon Nelson, D.O.; Lazlo I.

Belenyessy, M.D.; W.W. Mittelstadt, D.O., M.D.; Dr. Paul

Pybus

In Memoriam to Robert Bingham, the 1994 republication of

The Journal of the Rheumatoid Disease Medical Association

?

, is

being made by The Arthritis Trust of America. Editorial and sub-

scription office: c/o Perry A. Chapdelaine, Sr., The Arthritis Trust

of America

ฎ

, 7376 Walker Road, Fairview, TN. 1986 by The Rheu-

matoid Disease Medical Association, ISBN 0-930991-10-9.

For copies, $10 donation while they last.

Table of Contents

Editorial

Historical Note .

Free-Living Amoeba Roger Wyburn-Mason

Criteria and Treatment Methods Using Anti-Protozoa Drugs

Anti-amoebic Treatment for Rheumatoid Disease Gus J. Prosch,

Jr., M.D.

Hormone Balancing: Natural Treatment and Cure for Arthritis

Raymond F. Peat, Ph.D.

Conquest of the Amoebae Robert Bingham, M.D.

Adequate Treatment for Fighting Back Against Arthritis Robert

Bingham, M.D.

Subscription Form

Editorial

Volume One, Number One

As members of the Rheumatoid Disease Medical Associa-

tion, we are the physicians who realize, more than any others of

our profession, the seriousness of the arthritis problems which

we see every day in our practices of medicine.

In line following heart disease and cancer, the Rheumatoid

Diseases have become the third greatest cause of serious illnesses

and disabilities in the 1980s.

The origin of these rheumatoid diseases is still an enigma. But

the pioneer work of the late Dr. Roger Wyburn-Mason brought us

closer to the solution and has afforded us new approaches in diag-

nosis and treatment. This has been of great help to the practicing

physician who must deal with this family of diseases in his clinical

practice.

The Rheumatoid Disease Foundation is now going through a

metamorphosis from an organization promoting one theory — the

origin of rheumatoid arthritis caused by amoebae — and one treat-

ment — a protozoal drug — to a non-profit corporation supporting

medical research and dedicated to finding the causes and treatment

of all types of rheumatoid diseases, whatever their origins may be

and whatever method of management will benefit or cure the pa-

tient.

We have abundant clinical evidence that the rheumatoid dis-

eases are infectious in etiology. And the collected reports from our

members furnish more data and proof that the use of a variety of

medicines, which have an anti-protozoal action, are more effective

in producing improvement and remissions than drugs which are

commonly used for the signs and symptoms of these diseases. And

these are much safer and better tolerated by most patients.

Very many years ago, I had the privilege to work with the

Nobel prize winner, Rene Dubos, at the Rockefeller Institute for

Medical research in New York City. We used his discoveries of the

pioneer antibiotics, gramacidin and tyrocidin on some patients of

mine with osteomyelitis at the New York Orthopedic Hospital. It

turned out that we were the first to find out and demonstrate that

bacteria could develop an immunity to antibiotics.

Protozoa, being more complex because they are one celled

“animals” (often having more complex DNA) can be expected to

acquire immunity to antibiotics more quickly than lower forms of

pathogens. This may explain why such a drug as metronidazole

may lose its effect. This may require the physician to change

medications from time to time, particularly in chronic cases where

the disease has been treated with many types of anti-arthritic rem-

edies. [Metronidazole is not metabolized by the human enzyme

system. When good-guys micro-flora is knocked out — often by

metronidazole on the first usage — the next time with an over-

growth of Candida albicans or other organisms, the human body

simply does not metabolize the medicine thoroughly. On taking a

goodly supply of viable Lactobacillus acidophilus before, during,

and after ingestion of metronidazole, the medicine, the medicine

gets metabolized. This fact is not true of tinidazole or clotrimazole,

as the human enzyme system does metabolize the medicine. In the

case of metronidazole, the metabolites are the active ingredients,

not the metronidazole.]

Clinical information as simple as this may help the member of

the Rheumatoid Disease Medical Association in understanding the

drug problems of his patients and to manage them more success-

fully.

It is the hope and intent of your editor to select and publish

articles and clinical reports on new and better methods of therapy

so that this Journal will be of practical use to the physician who is

treating arthritis patients.

Since only about 15% of arthritis patients are treated by

rheumatologists — the other 85% by physicians in general prac-

tice, by specialists in internal medicine, by orthopedic surgeons and

by physical therapists and chiropractors — this Journal should

have a strong appeal and a wide circulation. Membership in our

new Association will be an honor as well as a source of valuable

clinical information. Your Case Reports, Reviews of Books and

articles and questions to our Scientific and Medical Advisory Com-

mittee will be welcome. This is your medical journal. Pass along

any news and clinical information which may be of interest to our

members.

No advertising can appear until we have a considerable num-

ber of paid subscribers. If you have not sent your dues or subscrip-

tions, please do so soon, so this new Journal can continue to grow

in size and in service to our membership, and through them to our

ฎ